Suspended

Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

What is being tested

Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc

Drug

Who is being recruted

Diabetes Mellitus+2

+ Endocrine System Diseases

+ Metabolic Diseases

+15 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-Controlled

Interventional

Study Start: August 2023

See protocol details

Summary

Principal SponsorNanjing First Hospital, Nanjing Medical University

Study ContactBingli Liu

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2023

Actual date on which the first participant was enrolled.

This study focuses on evaluating the long-term effects of various GLP-1 receptor agonists, like Duragtide, Semaglutide, and others, on patients with type 2 diabetes who have been managing the condition for 1 to 4 years. The research aims to understand how these medications impact body fat, insulin resistance, body weight, blood glucose levels, blood lipids, and stomach volume. By examining these factors, the study seeks to provide valuable evidence that can help improve treatment plans and outcomes for those living with type 2 diabetes, addressing current challenges in managing the disease. Participants in this study will receive treatment with one of the GLP-1 receptor agonists, administered as part of their diabetes management plan. Researchers will follow the participants over a period of 1 to 4 years to collect data on a variety of health indicators. The study will measure changes in body composition, blood sugar levels, and other metabolic parameters to determine the effectiveness of the treatment. This research may offer insights into how different medications can be tailored to better manage type 2 diabetes and improve patients' overall health and well-being.

Official TitleTherapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

NCT05990374

Principal SponsorNanjing First Hospital, Nanjing Medical University

Study ContactBingli Liu

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Diabetes MellitusEndocrine System DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesGlucose Metabolism Disorders

Criteria

6 inclusion criteria required to participate

HbA1c≥7.5%；

BMI>24kg/m2;

Subjects agree to maintain a scientific diet and exercise habits throughout the study, and regularly self-monitor and record blood sugar (SMBG);

Be willing to sign written informed consent and comply with the study protocol

Show More Criteria

9 exclusion criteria prevent from participating

Use of weight control drugs or surgery that can lead to weight instability within 2 months before screening, or are currently in a weight loss program and not in the maintenance stage:

had received coronary angioplasty, coronary stenting, or coronary artery bypass within 6 months before screening. Negligent compensatory heart failure (NYHA rating III and IV), stroke or transient ischemic attack, unstable angina, myocardial infarction, persistent and clinically significant arrhythmia;

Long-term (more than 7 consecutive days) intravenous administration, oral administration, or intra-articular administration of corticosteroids within 2 months prior to screening;

Use of any of the following drugs or treatments in the 3 months prior to screening: treatment with GLP-1RA, GLP-1 analogue, DPP-4 inhibitor, or any other incretin analogue;

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

7 intervention groups are designated in this study

14.286% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator